Huahai Pharmaceutical Ltd., a major Chinese API exporter, has expanded its capabilities to pharmaceutical finished products targeting mainly orders from NGOs.  The company said USFDA had inspected the company’s various API and formulation plants in March, and zero deficiency was found at its formulation plant. 

Huahai Pharma said that it is quite certain that it will receive USFDA approval for its Nevirapine formulation plant, thus will make it the first local Chinese pharmaceutical company to receive the USFDA approval for a pharmaceutical finished product.

The company disclosed that it may focus on API sales in EU markets, while concentrating on finished products in the US in future.  It founded a subsidiary in the US in 2005, and generated over US$3 million sales in the US market in 2006. 

In the long run, the company will transform itself from an API producer into a pharmaceutical company with core businesses in both APIs and pharmaceutical finished products. 

The company’s existing revenues mainly come from export sales of two categories of APIs, the -prils and –sartans, with US$345 million (+18.6%) and US$90 million (+63.4%) in 2006 sales respectively.